ES2422757T3 - Uso terapéutico de microesferas de ácido nucleico - Google Patents

Uso terapéutico de microesferas de ácido nucleico

Info

Publication number
ES2422757T3
ES2422757T3 ES08015799T ES08015799T ES2422757T3 ES 2422757 T3 ES2422757 T3 ES 2422757T3 ES 08015799 T ES08015799 T ES 08015799T ES 08015799 T ES08015799 T ES 08015799T ES 2422757 T3 ES2422757 T3 ES 2422757T3
Authority
ES
Spain
Prior art keywords
microspheres
nucleic acid
therapeutic use
nucleic acids
acid microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08015799T
Other languages
English (en)
Inventor
Terence L Scott
Debra Lafreniere
Vered Bisker-Leib
Larry R Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Application granted granted Critical
Publication of ES2422757T3 publication Critical patent/ES2422757T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)

Abstract

Microesferas que comprenden entre un 20 por ciento en peso y un 100 por cien en peso de uno o más ácidosnucleicos y que tienen un tamaño de partícula medio no superior a aproximadamente 50 micrómetros, estandodichas microesferas esencialmente libres de un polímero soluble utilizado en la preparación de lasmicroesferas, para su uso en terapia.
ES08015799T 2004-05-12 2005-05-12 Uso terapéutico de microesferas de ácido nucleico Active ES2422757T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57027304P 2004-05-12 2004-05-12
US62531104P 2004-11-05 2004-11-05

Publications (1)

Publication Number Publication Date
ES2422757T3 true ES2422757T3 (es) 2013-09-13

Family

ID=34969601

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08015799T Active ES2422757T3 (es) 2004-05-12 2005-05-12 Uso terapéutico de microesferas de ácido nucleico
ES05748256T Active ES2313350T3 (es) 2004-05-12 2005-05-12 Microesferas de acido nucleico, produccion y suministro de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05748256T Active ES2313350T3 (es) 2004-05-12 2005-05-12 Microesferas de acido nucleico, produccion y suministro de las mismas.

Country Status (12)

Country Link
US (2) US7815941B2 (es)
EP (3) EP2072040B1 (es)
JP (2) JP2007537284A (es)
AT (1) ATE409025T1 (es)
AU (1) AU2005244842B2 (es)
CA (1) CA2566079A1 (es)
DE (1) DE602005009954D1 (es)
DK (2) DK2072040T3 (es)
ES (2) ES2422757T3 (es)
MX (1) MXPA06012990A (es)
PT (1) PT1765294E (es)
WO (1) WO2005112894A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
EP1758558B1 (en) * 2004-05-12 2013-10-16 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
ATE409025T1 (de) * 2004-05-12 2008-10-15 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
JP2008539259A (ja) * 2005-04-27 2008-11-13 バクスター・インターナショナル・インコーポレイテッド 表面を修飾した微粒子およびその形成方法および使用
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
WO2008019346A2 (en) * 2006-08-04 2008-02-14 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
AU2013213750B2 (en) * 2006-08-04 2013-09-26 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
JP2010505882A (ja) * 2006-10-06 2010-02-25 バクスター・インターナショナル・インコーポレイテッド 表面改質微粒子を含むマイクロエンカプセルならびに、その形成および使用の方法
AU2008242842B2 (en) * 2007-04-17 2014-06-05 Baxter Healthcare Sa Nucleic acid microparticles for pulmonary delivery
WO2009129544A1 (en) * 2008-04-18 2009-10-22 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
JP5763525B2 (ja) * 2008-05-07 2015-08-12 サーモディクス，インコーポレイティド 粒子からの核酸複合体の送達
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201508149TA (en) 2010-10-01 2015-10-29 Moderna Therapeutics Inc Engineered nucleic acids and methods of use thereof
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX354267B (es) 2011-10-03 2018-02-21 Moderna Therapeutics Inc Star Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151671A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of cosmetic proteins and peptides
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160230174A1 (en) * 2013-09-26 2016-08-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tolerogenic dendritic cells to treat inflammatory bowel disease
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN116064746A (zh) * 2022-09-16 2023-05-05 上海伯杰医疗科技股份有限公司 用于核酸扩增的微球制剂、扩增方法及在联合检测中的应用

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US3726268A (en) * 1971-05-03 1973-04-10 R Stansell Cooking apparatus
BE786675A (fr) * 1971-08-02 1973-01-25 Airco Inc Separation d'oxydes d'alkyle halogenes par distillation azeotropique.
US3846332A (en) 1971-08-02 1974-11-05 Airco Inc Azeotropes of 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether with acetone, methyl ethylketone and tetrahydrofuran
US3897502A (en) * 1971-10-22 1975-07-29 Airco Inc Process for making fluorinated ethers
JPS523342B2 (es) 1972-01-26 1977-01-27
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4584894A (en) 1984-02-29 1986-04-29 Borg-Warner Corporation Transmission anti-clash and anti-rattle brake
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5102872A (en) 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
EP0248531A3 (en) 1986-05-02 1988-09-28 Southern Research Institute Encapsulated nucleic acids
EP0257915B1 (en) 1986-08-11 1993-03-10 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4762856A (en) * 1987-02-02 1988-08-09 Boc, Inc. Anesthetic composition and method of using the same
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5015781A (en) * 1988-05-06 1991-05-14 Boc, Inc. Anesthetic compound and method of preparing
US4874901A (en) 1988-05-06 1989-10-17 Boc, Inc. Process for the production of polyfluorinated ethers
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US4972040A (en) 1988-07-18 1990-11-20 Boc, Inc. Process for the preparation of CHF2 OCHFCF3
US4855511A (en) * 1988-07-18 1989-08-08 Boc, Inc. Process for preparing CHF2 OCHFCF3 and CHF2 OCHClCF3 and novel intermediate compounds employed therein
USRE38385E1 (en) 1989-02-16 2004-01-13 Nektar Therapeutics Storage of materials
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5026924A (en) * 1989-03-14 1991-06-25 Anaquest, Inc. Process for production of 1,2,2,2-tetrafluoroethyl difluoromethyl ether
DK0471036T4 (da) 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
DK0528978T3 (da) 1990-05-16 2003-02-17 Southern Res Inst Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
JPH0436233A (ja) * 1990-05-29 1992-02-06 Biomaterial Universe Kk 生理活性物質含有生体内分解吸収性の徐放性製剤
GB9016885D0 (en) 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
GB9023370D0 (en) * 1990-10-26 1990-12-05 Rhone Poulenc Chemicals Synthesis of fluorinated substituted ethanes
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
AU1442592A (en) 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5283372A (en) * 1991-12-04 1994-02-01 Anaquest, Inc. Preparation of purified optical isomers of desflurane
US5525519A (en) 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5173454A (en) 1992-01-09 1992-12-22 Corning Incorporated Nanocrystalline materials
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
DE4211169C1 (es) 1992-03-31 1993-06-03 Klaus Kretzschmar
JP2651320B2 (ja) 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
US5205914A (en) * 1992-08-14 1993-04-27 Anaquest, Inc. Synthesis of desflurane
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
EP0595030A3 (en) 1992-10-01 1995-06-07 Tanabe Seiyaku Co Composition of microspheres with several delayed release nuclei and its preparation process.
EP0674506B1 (en) 1992-12-02 2000-08-23 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
WO1994018947A1 (en) * 1993-02-16 1994-09-01 Sharifa Karali High purity protamine-dna complex and use of same
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ATE258685T1 (de) 1993-03-09 2004-02-15 Baxter Int Makromolekulare mikropartikel und verfahren zur ihrer herstellung
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5932248A (en) 1993-11-18 1999-08-03 Paragon Medical Limited Controlled release preparations for cytotoxic or cytostatic drugs
AU684324B2 (en) 1993-11-19 1997-12-11 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5858973A (en) 1994-02-23 1999-01-12 The General Hospital Corporation Transcription factor and uses therefor
US5972707A (en) 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
JPH10503769A (ja) 1994-08-04 1998-04-07 クアドラント ホールディングス ケンブリッジ リミテッド 配合されている分子の制御放出用の固形放出系およびその製造方法
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5542920A (en) 1994-09-12 1996-08-06 Delab Needle-less parenteral introduction device
US6387399B1 (en) 1994-12-02 2002-05-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulated bioactive agents and method of making
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5958769A (en) * 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
GB9607035D0 (en) 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
US6077833A (en) 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
JP2002514215A (ja) 1997-04-17 2002-05-14 アムジエン・インコーポレーテツド 治療薬の徐放送達のための生分解性微粒子
DK1017365T3 (da) * 1997-06-23 2004-03-29 Alza Corp Liposomomsluttet polynukleotidsammensætning og fremgangsmåde
US6153211A (en) 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6042792A (en) * 1997-09-18 2000-03-28 International Flavors & Fragrances Inc. Apparatus for preparing a solid phase microparticulate composition
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP1045700B1 (en) * 1998-01-16 2004-11-10 The Johns Hopkins University Oral delivery of nucleic acid vaccines by particulate complexes
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6395253B2 (en) 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
US6197584B1 (en) 1998-05-01 2001-03-06 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 expression
JP4538150B2 (ja) 1998-08-14 2010-09-08 ヴァレンティス，インコーポレイテッド 核酸分子の保護された単一バイアル調製物、インライン混合によってそれを形成する方法、及び関連する生成物及び方法
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
ATE241965T1 (de) * 1999-01-13 2003-06-15 Univ Johns Hopkins Med Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
CA2373016A1 (en) 1999-05-04 2000-11-09 Genethor Gmbh Method for diminishing specific immune reactions
DE69910987T2 (de) 1999-06-14 2004-05-19 Baxter International Inc., Deerfield Mikrosphären mit verzögerter Wirkstoffabgabe
EP1194128A2 (en) 1999-06-23 2002-04-10 Sedum Laboratories Ionically formulated biomolecule microcarriers
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
FR2809309B1 (fr) 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
KR100831118B1 (ko) 2000-05-26 2008-05-20 심포젠 에이/에스 알레르기를 치료하기 위한 재조합 폴리클로날 항체 또는정제된 폴리클로날 항체
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
EP1801123A3 (en) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7833525B2 (en) 2000-12-28 2010-11-16 Bhami Shenoy Crystals of whole antibodies and fragments thereof and methods for making and using them
US6896905B2 (en) 2001-02-15 2005-05-24 Rohm And Haas Company Porous particles, their aqueous dispersions, and method of preparation
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP2005500304A (ja) 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030064033A1 (en) 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
GB0207440D0 (en) * 2002-03-28 2002-05-08 Ppl Therapeutics Scotland Ltd Tolerogenic antigen-presenting cells
WO2005123131A2 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
EP1507874A4 (en) 2002-05-28 2006-06-28 Mirus Bio Corp COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION USING POLYNUCLEOTIDES
US6900998B2 (en) 2002-05-31 2005-05-31 Midwest Research Institute Variable-speed wind power system with improved energy capture via multilevel conversion
AU2003251592A1 (en) 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040014698A1 (en) 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20060002862A1 (en) 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
EP1581639A4 (en) 2002-12-17 2006-03-08 Medimmune Vaccines Inc HIGH PRESSURE PULVISATION OF BIOACTIVE MATERIALS
AU2003291527A1 (en) 2002-12-31 2004-07-29 Nektar Therapeutics Antibody-containing particles and compositions
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
LT2335725T (lt) 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
ES2216707B1 (es) 2003-04-08 2005-12-16 Josep Maria Aran Perramon Secuencia oligoribonucleotidica homologa a una region del cdna que codifica para el receptor cd40 humano y oligoribonucleotidos duplex, vectores, composiciones farmaceuticas y usos correspondientes.
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
CN1845938B (zh) 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
US7066023B2 (en) 2003-07-14 2006-06-27 Environmental Security Corporation Distributed sensor array for fluid contaminant monitoring
CA2532837A1 (en) 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical particles by controlled phase separation
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2005067971A1 (ja) * 2004-01-16 2005-07-28 Takeda Pharmaceutical Company Limited 動脈硬化の予防・治療用医薬
EP1713332A4 (en) 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHOD FOR INDUCTION OF IMMUNOTHERAPY AND IMMUNOSUPPRESSION
JP2007522157A (ja) 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
EP1758558B1 (en) * 2004-05-12 2013-10-16 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
ATE409025T1 (de) * 2004-05-12 2008-10-15 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006072527A1 (de) 2005-01-05 2006-07-13 Siemens Aktiengesellschaft Head-up-display für ein kraftfahrzeug
JP4595112B2 (ja) 2005-02-14 2010-12-08 独立行政法人産業技術総合研究所 タンパク質の高効率分離または濃縮方法
US7785595B2 (en) 2005-04-18 2010-08-31 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
RU2303833C2 (ru) 2005-07-26 2007-07-27 Самсунг Электро-Меканикс Ко., Лтд. Осветительное устройство
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途

Also Published As

Publication number Publication date
EP1765294A1 (en) 2007-03-28
MXPA06012990A (es) 2007-02-12
EP2072040B1 (en) 2013-05-01
EP1765294B1 (en) 2008-09-24
ATE409025T1 (de) 2008-10-15
JP2007537284A (ja) 2007-12-20
AU2005244842A1 (en) 2005-12-01
US20110033551A1 (en) 2011-02-10
CA2566079A1 (en) 2005-12-01
EP2072040A1 (en) 2009-06-24
DE602005009954D1 (de) 2008-11-06
AU2005244842B2 (en) 2010-09-23
US9339465B2 (en) 2016-05-17
ES2313350T3 (es) 2009-03-01
EP2335689A1 (en) 2011-06-22
PT1765294E (pt) 2008-12-30
US7815941B2 (en) 2010-10-19
US20060018971A1 (en) 2006-01-26
DK2072040T3 (da) 2013-07-29
WO2005112894A1 (en) 2005-12-01
JP2011256203A (ja) 2011-12-22
DK1765294T3 (da) 2008-11-10

Similar Documents

Publication Publication Date Title
ES2422757T3 (es) Uso terapéutico de microesferas de ácido nucleico
ATE374598T1 (de) Mikropartikel und verfahren zur deren herstellung
ATE304349T1 (de) Herstellungsverfahren von submikrometerwirkstoffpartikeln
DE60107872D1 (de) Herstellung von wirkstoffpartikeln durch evaporation-präzipitation in wässrige lösungen
DE69906269T2 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
BRPI0416038A (pt) gel baseado em tensoativo como um veìculo injetável de liberação sustentada de droga
BR0307515A (pt) Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
PT1033973E (pt) Metodo de encapsulacao
EA200600703A1 (ru) Композиции активных веществ в форме наночастиц
DE602005023566D1 (de) Verfahren zur Herstellung von Hydrophob modifizierten Polymere
JP2000252242A5 (es)
CN106757785B (zh) 一种载银壳聚糖/聚乙烯醇微米带的制备方法
DE69904701D1 (de) Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
DE602004026096D1 (de) Verfahren zur herstellung von polyacrolein
ATE366565T1 (de) Stabilisierung mit substituierten harnstoffen gegen farbabbau von körperpflegeprodukten
BRPI0416523A (pt) processo de produção de sais metálicos do ácido trifluormetano sulfÈnico e usos dos mesmos
ATE514746T1 (de) Kohlenstoffnanoröhrchen verstärkte polymerzusammensetzung und verfahren zu deren herstellung
JP2007510037A5 (es)
BRPI0411751A (pt) processo de polimerização para preparação de
DE69631602D1 (de) Wässrige dispersionen von polyamiden
BR0205251A (pt) Composição reticulável, método para fornecer um artigo compreendendo um polìmero reticulável, e, processo para formar uma composição reticulável
BR9916762A (pt) Composição de condicionamento do cabelo
TW200506531A (en) Photoresist composition for deep uv and process thereof
DE60125226D1 (de) Verfahren zur herstellung von partikelförmigen polymerisaten
DE60230298D1 (de) Herstellung von mikropartikeln